Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

SNTI - Senti Biosciences Inc.


IEX Last Trade
2.65
-0.060   -2.264%

Share volume: 6,992
Last Updated: Fri 30 Aug 2024 09:53:22 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$2.71
-0.06
-2.21%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
13%
Profitability 0%
Dept financing 11%
Liquidity 75%
Performance 10%
Company vs Stock growth
vs
Performance
5 Days
-8.30%
1 Month
13.25%
3 Months
-15.34%
6 Months
-38.61%
1 Year
-59.23%
2 Year
-86.20%
Key data
Stock price
$2.65
P/E Ratio 
-0.21
DAY RANGE
N/A - N/A
EPS 
-$16.34
52 WEEK RANGE
$1.52 - $8.48
52 WEEK CHANGE
-$0.61
MARKET CAP 
12.134 M
YIELD 
N/A
SHARES OUTSTANDING 
4.579 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$34,734
AVERAGE 30 VOLUME 
$89,542
Company detail
CEO:
Region: US
Website:
Employees: 122
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

senti biosciences is a team of engineers, scientists, and entrepreneurs on a mission to leverage synthetic biology to treat the most pressing diseases. they have pioneered new technology platforms to design synthetic gene circuits for adaptive cell and gene therapies. their recently completed series a round of funding will be used to further the growth of their scalable therapeutic design platform and advance therapeutic candidates towards the clinic. they are proud to count nea, 8vc, amgen ventures, pear ventures, lux capital, menlo ventures, allen & company, nest.bio, omega funds, goodman capital, and lifeforce capital among their investors.

Recent news